NRTUA treatment of tumor-bearing mice at tumor sites rapidly increased the production of TH1 cytokines interleukin 12 (IL-12) and IFN-γ and activated tumor-associated and splenic CD8+ and CD4+ T cells [21, 25, 27]. This evidence concerns the gene IFNG and neoplasm.